Moderna shares plunged one day after their historic 177% rally, erasing approximately $14.2 billion from the biotechnology company’s market value as investors reassessed the valuation created by its cancer-treatment breakthrough. MRNA traded near $138.89 at 10:31 a.m.
Visit Website
